{"id":"ocrevus-us","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Herpes simplex virus reactivation"},{"rate":"null","effect":"Upper respiratory tract infections"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ocrevus-US works by binding to CD20, leading to the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis. This results in a reduction in disease activity and slowing of disease progression.","oneSentence":"Ocrevus-US is a monoclonal antibody that targets CD20 on B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:51.402Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06847724","phase":"PHASE3","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Sandoz","startDate":"2025-06-10","conditions":"Relapsing Multiple Sclerosis","enrollment":175},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ocrelizumab"],"phase":"phase_3","status":"active","brandName":"Ocrevus-US","genericName":"Ocrevus-US","companyName":"Sandoz","companyId":"sandoz","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ocrevus-US is a monoclonal antibody that targets CD20 on B cells. Used for Relapsing multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}